Regulus Therapeutics reported $187K in Interest Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Alnylam Pharmaceuticals ALNY:US USD 7.82M 5.92M
Biogen BIIB:US USD 23.9M 11.3M
Intrexon XON:US USD 56K 19K
Regulus Therapeutics RGLS:US USD 187K 108K
Sangamo BioSciences SGMO:US USD 1.77M 874K
Vital Therapies VTL:US USD 230K 124K